Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01178411 · MORE INFO

Limitations, agreements, and source contact

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols · Source last updated 2021-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The Investigator shall have the right to publish the results of research performed under this protocol, provided that such publication does not disclose any confidential information or trade secrets of ArQule (other than the data).
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialsDisclosure@merck.com
organization
Merck Sharp & Dohme Corp.
phone
1-800-672-6372
title
Senior Vice President, Global Clinical Development
Complete source fields
certain Agreement
other Details
The Investigator shall have the right to publish the results of research performed under this protocol, provided that such publication does not disclose any confidential information or trade secrets of ArQule (other than the data).
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialsDisclosure@merck.com
organization
Merck Sharp & Dohme Corp.
phone
1-800-672-6372
title
Senior Vice President, Global Clinical Development

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice